Correction to “Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study”
2026
Read Correction to “Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study” (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13443131.txt.
Description
Wang and colleagues published a correction in 2026 to their phase II study, which tested three drugs given before surgery for HER2-positive locally advanced stomach cancer. The notice fixes a series of numbers. The count of patients classified HER2 3+ rises from 15 to 16. Several response-rate percentages in Tables 4 to 6 are replaced. Two p-values are also corrected. One subgroup's major response rate moves from about six percent to about twenty-five percent. All corrected comparisons remain statistically non-significant.
Catalog record
| YEAR | 2026 |
|---|---|
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |